Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays

Blood

Volumn 98, Issue 3, 2001, Pages 771-780

  De Vos, John ^a   Couderc, Guilhem ^a   Tarte, Karin ^a   Jourdan, Michel ^a   Requirand, Guilhem ^a   Delteil, Marie Claude ^a   Rossi, Jean François ^a   Mechti, Nadir ^a   Klein, Bernard ^a,b  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; COMPLEMENTARY DNA; FRIZZLED RELATED PROTEIN; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; INTERLEUKIN 6; LIGAND; NOTCH RECEPTOR; PROTEIN JAGGED 2; SYNDECAN 1; THROMBIN RECEPTOR; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; WNT PROTEIN;

ARTICLE; AUTOCRINE EFFECT; B LYMPHOBLAST; BONE MARROW CELL; CELL GROWTH; CELL INVASION; CONTROLLED STUDY; DNA MICROARRAY; FRZB GENE; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE ISOLATION; GENE OVEREXPRESSION; HB EGF GENE; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PLASMA CELL; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN PURIFICATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TR GENE; TUMOR GROWTH; TYRO3 GENE;

EID: 0035437195     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.3.771     Document Type: Article

References (75)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
2. Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 1999;59:728-733.
3. Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood. 1999;93:3064-3073.
4. Dankbar B, Padro T, Leo R, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood. 2000;95:2630-2636.
5. Stauder R, Van Driel M, Schwarzler C, et al. Different CD44 splicing patterns define prognostic subgroups in multiple myeloma. Blood. 1996;88:3101-3108.
6. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myelomaderived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood. 1993;82:3712-3720.
7. Lokhorst HM, Lamme T, de Smet M, et al. Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. Blood. 1994;84:2269-2277.
8. Klein B, Zhang XG, Jourdan M, et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood. 1989;73:517-526.
9. Costes V, Portier M, Lu ZY, Rossi JF, Bataille R, Klein B. Interleukin-1 in multiple myeloma: producer cells and their role in the control of IL-6 production. Br J Haematol. 1998;103:1152-1160.
10. Donovan KA, Lacy MQ, Kline MP, et al. Contrast in cytokine expression between patients with monoclonal gammopathy of undetermined significance or multiple myeloma. Leukemia. 1998;12:593-600.
11. Kawano M, Tanaka H, Ishikawa H, et al. Interleukin-1 accelerates autocrine growth of myeloma cells through interleukin-6 in human myeloma. Blood. 1989;73:2145-2148.
12. Gu ZJ, De Vos J, Rebouissou C, et al. Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors. Leukemia. 2000;14:188-197.
13. Degrassi A, Hibert DM, Rudikoff S, Anderson AO, Potter M, Coon HG. In vitro culture of primary plasmacytomas requires stromal cell feeder layers. Proc Natl Acad Sci U S A. 1993;90:2060-2064.
14. Bloem AC, Lamme T, de Smet M, et al. Long-term bone marrow cultured stromal cells regulate myeloma tumour growth in vitro: studies with primary tumour cells and LTBMC-dependent cell lines. Br J Haematol. 1998;100:166-175.
15. Van Riet I, De Greef C, Aharchi F, et al. Establishment and characterization of a human stromadependent myeloma cell line (MM5.1) and its stroma-independent variant (MM5.2). Leukemia. 1997;11:284-293.
16. Chesi M, Nardini E, Brents LA, et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet. 1997;16:260-264.
17. Plowright EE, Li Z, Bergsagel PL, et al. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood. 2000;95:992-998.
18. Costes V, Magen V, Legouffe E, et al. The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens. Hum Pathol. 1999;30:1405-1411.
19. Steinfeld R, Van Den Berghe H, David G. Stimulation of fibroblast growth factor receptor-1 occupancy and signaling by cell surface-associated syndecans and glypican. J Cell Biol. 1996;133:405-416.
20. Ferlin M, Noraz N, Hertogh C, Brochier J, Taylor N, Klein B. Insulin-like growth factor induces the survival and proliferation of myeloma cells through an IL-6-independent transduction pathway. Br J Haematol. 2000;111:626-634.
21. Jelinek DF, Witzig TE, Arendt BK. A role for insulin-like growth factor in the regulation of IL-6responsive human myeloma cell line growth. J Immunol. 1997;159:487-496.
22. Georgil-Hemming P, Wiklund HJ, Ljunggren O, Nilsson K. Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines. Blood. 1996;88:2250-2258.
23. Zhang XG, Gaillard JP, Robillard N, et al. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood. 1994;83:3654-3663.
24. Rebouissou C, Wijdenes J, Autissier P, et al. A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma. Blood. 1998;91:4727-4737.
25. Tarte K, Zhang XG, Legouffe E, et al. Induced expression of B7-1 on myeloma cells following retroviral gene transfer results in tumor-specific recognition by cytotoxic T cells. J Immunol. 1999;163:514-524.
26. Sun RX, Lu ZY, Wijdenes J, et al. Large scale and clinical grade purification of syndecan-1 + malignant plasma cells. J Immunol Methods. 1997;205:73-79.
27. Commes T, Clofent G, Ghanem N, et al. Analysis of the B-cell compartment in plasma cell leukemia and multiple myeloma: immunoglobulin gene rearrangement of EBV-infected B cell lines. Leukemia. 1993;7:609-618.
28. Tarte K, Fiol G, Legouffe E, Rossi JF, Klein B. Generation of polyclonal plasma cells from peripheral blood B cells: how to get a normal counterpart of malignant plasma cells [abstract]. Blood. 2000;96:514a.
29. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998;95:14863-14868.
30. De Vos J, Jourdan M, Tarte K, Jasmin C, Klein B. JAK2 tyrosine kinase inhibitor tyrphostin AG490 down-regulates the MAPK and STAT pathways and induces apoptosis in myeloma cells. Br J Haematol. 2000;109:823-828.
31. Wimmel A, Rohner I, Ramaswamy A, et al. Synthesis and secretion of the anticoagulant protein S and coexpression of the Tyro3 receptor in human lung carcinoma cells. Cancer. 1999;86:43-49.
32. Klein B, Zhang XG, Rossi JF. Cytokines, cytokine receptors and signal transduction in human multiple myeloma. In: Malpas JS, Bergsagel DE, Kyle RA, Anderson KC, eds. Myeloma: Biology and Management. Oxford, United Kingdom: Oxford University Press; 1998:70-88.
33. Hallek M, Leif BP, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 1998;91:3-21.
34. Gibbons DL, Rowe M, Cope AP, Feldmann M, Brennan FM. Lymphotoxin acts as an autocrine growth factor for Epstein-Barr virus-transformed B cells and differentiated Burkitt lymphoma cell lines. Eur J Immunol. 1994;24:1879-1885.
35. Estrov Z, Kurzrock R, Pocsik E, et al. Lymphotoxin is an autocrine growth factor for EpsteinBarr virus-infected B cell lines. J Exp Med. 1993;177:763-774.
36. Tosato G, Tanner J, Jones KD, Revel M, Pike SE. Identification of interleukin-6 as an autocrine growth factor for Epstein-Barr virus-immortalized B cells. J Virol. 1990;64:3033-3041.
37. Jourdan M, Tarte K, Legouffe E, Brochier J, Rossi JF, Klein B. Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. Eur Cytokine Netw. 1999;10:65-70.
38. Lichtenstein A, Berenson J, Norman D, Chang MP, Carlile A. Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood. 1989;74:1266-1273.
39. Portier M, Zhang XG, Ursule E, et al. Cytokine gene expression in human multiple myeloma. Br J Haematol, 1993;85:514-520.
40. Bertoglio J, Interleukin 1 and interleukin 1 receptors in human B-cell lines. Lymphokine Res. 1989;8:301-304.
41. Gruss HJ, Dower SK. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Cytokines Mol Ther. 1995;85:3378-3404.
42. Klein SC, Jucker M, Abts H, Tesch H. IL6 and IL6 receptor expression in Burkitt's lymphoma and lymphoblastoid cell lines: promotion of IL6 receptor expression by EBV. Hematol Oncol. 1995;13:121-130.
43. Arora T, Jelinek DF. Differential myeloma cell responsiveness to interferon-alpha correlates with differential induction of p19(INK4d) and cyclin D2 expression. J Biol Chem, 1998;273:11799-11805.
44. Jelinek DF. Mechanisms of myeloma cell growth control. Hematol Oncol Clin North Am. 1999;13:1145-1157.
45. Crosier KE, Crosier PS. New insights into the control of cell growth: the role of the Axl family. Pathology. 1997;29:131-135.
46. O'Bryan JP, Frye RA, Cogswell PC, et al. axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol. 1991;11:5016-5031.
47. Taylor IC, Roy S, Yaswen P, Stampfer MR, Varmus HE. Mouse mammary tumors express elevated levels of RNA encoding the murine homology of SKY, a putative receptor tyrosine kinase. J Biol Chem. 1995;270:6872-6880.
48. Lan Z, Wu H, Li W, et al. Transforming activity of receptor tyrosine kinase tyro3 is mediated, at least in part, by the PI3 kinase-signaling pathway. Blood. 2000;95:633-638.
49. Besser D, Bromberg JF, Darnell JE Jr, Hanafusa H. A single amino acid substitution in the v-Eyk intracellular domain results in activation of Stat3 and enhances cellular transformation. Mol Cell Biol. 1999;19:1401-1409.
50. Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999;10:105-115.
51. Dirks W, Rome D, Ringel F, Jager K, MacLeod RA, Drexler HG. Expression of the growth arrestspecific gene 6 (GAS6) in leukemia and lymphoma cell lines. Leuk Res. 1999;23:643-651.
52. Avanzi GC, Gallicchio M, Cavalloni G, et al. GAS6, the ligand of Axl and Rse receptors, is expressed in hematopoietic tissue but lacks mitogenic activity. Exp Hematol. 1997;25:1219-1226.
53. Davis-Fleischer KM, Besner GE. Structure and function of heparin-binding EGF-like growth factor (HB-EGF). Front Biosci. 1998;3:d288-299.
54. Elenius K, Paul S, Allison G, Sun J, Klagsbrun M. Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation. EMBO J. 1997;16:1268-1278.
55. Qiu Y, Ravi L, Kung HJ. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature. 1998;393:83-85.
56. Kleeff J, Ishiwata T, Kumbasar A, et al. The cellsurface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest. 1998;102:1662-1673.
57. Coughlin SR. How the protease thrombin talks to cells. Proc Natl Acad Sci U S A. 1999;96:1102311027.
58. Subramanian SV, Fitzgerald ML, Bernfield M. Regulated shedding of syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation. J Biol Chem. 1997;272:14713-14720.
59. Klein B, Li XY, Lu ZY, et al. Activation molecules on human myeloma cells. Curr Top Microbiol Immunol. 1999;246:335-341.
60. Seidel C, Sundan A, Hjorth M, et al. Serum syndecan-1: a new independent prognostic marker in multiple myeloma [published erratum appears in Blood. 2000 Apr 1;95(7):2197]. Blood. 2000;95:388-392.
61. Prenzel N, Zwick E, Daub H, et al. EGF receptor transactivation by G- protein-coupled receptors requires metalloproteinase cleavage of proHBEGF. Nature. 1999;402:884-888.
62. Even-Ram S, Uziely B, Cohen P, et al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med. 1998;4:909-914.
63. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol. 2000;18:217-242.
64. Peled A, Petit I, Kollet O, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science. 1999;283:845-848.
65. Ma Q, Jones D, Borghesani PR, et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci U S A. 1998;95:9448-9453.
66. Vande Broek I, Vanderkerken K, Straetmans N, Van Camp B, Van Riet I. The chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates chemotaxis to monocyte chemotactic proteins MCP-1, 2 and 3 [abstract]. Blood. 2000;96:473a.
67. Woodliff JE, Engel BC, Epstein J. Myeloma cells homing to the bone marrow is directed by CXCR4/SDF-1 interactions [abstract]. Blood. 2000;96:550a.
68. Pennisi E. How a growth control path takes a wrong turn to cancer [published erratum appears in Science. 1998 Sep 18;281:1809]. Science. 1998;281:1438-1439, 1441.
69. Hoang B, Moos M, Jr, Vukicevic S, Luyten FP. Primary structure and tissue distribution of FRZB, a novel protein related to Drosophila frizzled, suggest a role in skeletal morphogenesis. J Biol Chem. 1996;271:26131-26137.
70. Wang S, Krinks M, Lin K, Luyten FP, Moos MJ. Frzb, a secreted protein expressed in the Spemann organizer, binds and inhibits Wnt-8. Cell. 1997;88:757-766.
71. Milner LA, Bigas A. Notch as a mediator of cell fate determination in hematopoiesis: evidence and speculation. Blood. 1999;93:2431-2448.
72. Ellisen LW, Bird J, West DC, et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell. 1991;66:649-661.
73. Artavanis-Tsakonas S, Matsuno K, Fortini ME. Notch signaling. Science. 1995;268:225-232.
74. Pear WS, Aster JC, Scott ML, et al. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J Exp Med. 1996;183:2283-2291.
75. Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood. 1995;85:863-872.